Discovery of 3-methacylic acid substituted benzoxaboroles as dual metallo- and serine-β-lactamase inhibitors
- 8 May 2025
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 293, 117723
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82122065)
- National Natural Science Foundation of China (82473845)
- Sichuan Provincial Science and Technology Support Program (2025ZNSFSC0686)
- Sichuan Provincial Science and Technology Support Program (2025YFHZ0085)
This publication has 25 references indexed in Scilit:
- Metallo-β-lactamase-mediated antimicrobial resistance and progress in inhibitor discoveryTrends in Microbiology, 2023
- Recent advances in β-lactamase inhibitor chemotypes and inhibition modesEuropean Journal of Medicinal Chemistry, 2022
- Targeting Metalloenzymes by Boron-Containing Metal-Binding PharmacophoresJournal of Medicinal Chemistry, 2021
- Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor DesignChemical Reviews, 2021
- Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamasesBioorganic & Medicinal Chemistry Letters, 2021
- Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-LactamasesJournal of Medicinal Chemistry, 2020
- Principles and current strategies targeting metallo‐β‐lactamase mediated antibacterial resistanceMedicinal Research Reviews, 2020
- Inhibitors of metallo-β-lactamasesCurrent Opinion in Microbiology, 2017
- Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases2015
- Synthesis and Biological Evaluation of Novel Benzoxaboroles as Potential Antimicrobial and Anticancer AgentsJournal of Heterocyclic Chemistry, 2013